https://www.selleckchem.com/pr....oducts/NVP-TAE684.ht
Here, We examined the role of EP-100 (luteinizing hormone-releasing hormone (LHRH) ligand joined to a lytic peptide), improving the efficacy of immune checkpoint blockade. LHRH-R-positive murine ovarian cancer cells (ID8, IG10, IF5, and 2C12) were sensitive to EP-100 and were specifically killed at low micromolar levels through LHRH-R. EP-100 increased PD-L1 levels on murine ovarian cancer cells. In vivo syngeneic mouse models (ID8 and IG1 demonstrated that single-agent EP-100 reduced tumor volume, tumor weight, and ascites volume.
Like
Comment
Share
